AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38775275
Drug: Weekly surveys
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly surveys and biweekly nasal sampling
Trial: 38775632
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored oral health intervention provided by a dental hygienist focusing on oral hygiene and self-care.
Trial: 38775910
Drug: Fixed-Dose Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-Dose Combination Product (FDCP) of amlodipine, losartan, ezetimibe, and rosuvastatin
Trial: 38775910
Drug: Individual tablets
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual tablets of amlodipine, losartan, ezetimibe, and rosuvastatin
Trial: 38775910
Drug: Fixed-Dose Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-Dose Combination Product (FDCP)
Trial: 38776391
Drug: BNT142 RNA-LNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT142 RNA-LNP (0.1- to 1-μg dose range)
Trial: 38776484
Drug: Ruxolitinib 15
RxNorm normalized name: ruxolitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 15 mg PO twice a day with paclitaxel/carboplatin chemotherapy
Trial: 38776484
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (paclitaxel/carboplatin)
Trial: 38776515
Drug: Treatment options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment options based on PROSPECT trial data
Trial: 38776517
Drug: Artificial intelligence
RxNorm normalized name: Intelence
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artificial intelligence in treatment planning
Trial: 38776543
Drug: Antimicrobial Photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial Photodynamic Therapy (a specific intervention for root canal disinfection)
Trial: 38776635
Drug: Intervention M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention M (influenza vaccine messaging platform: video, flyer, scripted message, vaccine acceptance question, provider notification)
Trial: 38776635
Drug: Intervention Q
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Q (no messaging, vaccine acceptance question, provider notification)
Trial: 38776754
Drug: Dietary sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary sulfur amino acid restriction (SAAR) (∼2 g SAA)
Trial: 38776754
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (∼5.6 g SAA)
Trial: 38776914
Drug: Iberdomide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide treatment
Trial: 38777276
Drug: Maudsley Staging
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maudsley Staging Method treatment-resistance scores
Trial: 38778264
Drug: Morning light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning light treatment for 4 weeks
Trial: 38778264
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) for 4 weeks
Trial: 38778803
Drug: ECPR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECPR treatment
Trial: 38779740
Drug: Defibrotide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (25 mg/kg intravenously, divided into four daily doses over 14 days)
Trial: 38779911
Drug: Targeted treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted treatments based on molecular profiling (24 drugs available)
Trial: 38780185
Drug: App-based mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based mental training (MT) for 3 months, daily 10-minute sessions
Trial: 38780927
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg IV every 2 weeks for 5 cycles during IMRT, then 480 mg IV every 4 weeks for a total of 52 weeks)
Trial: 38780959
Drug: Combined Airway
RxNorm normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Airway and Positional Therapy (CAPT)
Trial: 38781428
Drug: Secondary mitral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary mitral regurgitation (MR) with MR volume ≥ 24 mL
Trial: 38781591
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (maintained on antihypertensive therapy with a goal BP below 140/90 mm Hg)
Trial: 38781634
Drug: Contraceptive switching
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive switching or discontinuation
Trial: 38781634
Drug: Both switching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both switching and discontinuation
Trial: 38781634
Drug: Discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation
Trial: 38781634
Drug: Subsequent method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent method after discontinuation
Trial: 38781664
Drug: Chlorthalidone/amiloride 25/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone/amiloride 25/5 mg
Trial: 38781965
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICIs) treatment, with or without chemotherapy, for front-/subsequent-line therapy.
Trial: 38782015
Drug: Arimoclomol citrate
RxNorm normalized name: ARIMOCLOMOL CITRATE
DrugBank: Arimoclomol (DB05025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arimoclomol citrate 1200 mg/day (400 mg three times per day)
Trial: 38782542
Drug: EVX-01 (personalized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVX-01 (personalized peptide-based neoantigen vaccine)
Trial: 38782609
Drug: Crushed venetoclax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed venetoclax tablets
Trial: 38782609
Drug: Ground venetoclax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground venetoclax tablets
Trial: 38782609
Drug: Intact venetoclax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact venetoclax tablets
Trial: 38782726
Drug: Volenrelaxin (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volenrelaxin (intravenous or subcutaneous)
Trial: 38782726
Drug: Volenrelaxin (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volenrelaxin (subcutaneous once weekly for 5 weeks)
Trial: 38783176
Drug: MAF capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAF capsules
Trial: 38783176
Drug: M capsules
RxNorm normalized name: Menofem Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M capsules
Trial: 38783205
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment program over 24 weeks
Trial: 38783238
Drug: Nivolumab (anti-PD-1)
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (anti-PD-1) maintenance therapy discontinued early after achieving CR/PR
Trial: 38783836
Drug: Computer-Based Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-Based Training for Cognitive Behavioural Therapy (CBT4CBT)
Trial: 38784165
Drug: Mobile app-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile app-based self-guided psychological intervention (Nałogometr 2.0) incorporating mindfulness techniques and Cognitive Behavioral Therapy (CBT) principles over three months.
Trial: 38784617
Drug: LIFEwithIBD intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LIFEwithIBD intervention (Acceptance and Commitment Therapy and compassion-based intervention)
Trial: 38785314
Drug: Enhanced hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced hydration (20 mL/kg body weight, one-third given via bolus and remainder over 8 hours)
Trial: 38785314
Drug: Standard hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hydration (60 mL/h for 8 hours, followed by maintenance infusion of 40-80 mL/h for the subsequent 64 hours)
Trial: 38785484
Drug: Ultrahypofractionated (UHF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrahypofractionated (UHF) MRI-guided radiotherapy on a 1.5 T MR-Linac with a dose of 42.7 Gy in seven fractions
Trial: 38787562
Drug: Remote, pushed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote, pushed digital assessments and engagement (monthly text messaging about mental health, mental health assessments, and linkages to care)
Trial: 38788175
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) treatment in good-grade aSAH (N = 232)
Trial: 38788175
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) treatment in poor-grade aSAH (N = 162)
Trial: 38788821
Drug: TEER with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEER with MitraClip device plus guideline-directed medical therapy (GDMT)
Trial: 38788904
Drug: Intraprostatic injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic injection of 1 g of tranexamic acid (TXA) dissolved in 50 mL of 0.9% saline at multiple sites
Trial: 38788904
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL saline injection (Control)
Trial: 38788907
Drug: Adjuvant letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant letrozole 2.5 mg/day
Trial: 38789134
Drug: Ferrous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous iron (Ferrous succinate sustained-release tablet 0.2 g corresponding to 70 mg of elemental iron) once daily for 12 weeks
Trial: 38789134
Drug: Placebo (similar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similar in colour, smell, and size to ferrous iron) once daily for 12 weeks
Trial: 38789134
Drug: Ferrous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous iron (Ferrous succinate sustained-release tablet 0.2 g)
Trial: 38789142
Drug: Proactive e-alcohol
RxNorm normalized name: (E)-cinnamyl alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive e-alcohol therapy
Trial: 38789363
Drug: Maintenance of
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of beta-blockers
Trial: 38789602
Drug: Epinephrine (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.03 mcg/kg/min)
Trial: 38789602
Drug: Phenylephrine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (0.4 mcg/kg/min)
Trial: 38789656
Drug: Rose geranium
RxNorm normalized name: ALCOHOL 62 mL in 100 mL TOPICAL SPRAY [All Good Rose Geranium Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rose geranium in sesame oil (RG) nasal spray, administered twice daily for 2 weeks
Trial: 38789656
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (IS) nasal spray, administered twice daily for 2 weeks
Trial: 38789924
Drug: Giredestrant plus
RxNorm normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC)
Trial: 38789924
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus optional endocrine therapy (ET)
Trial: 38790057
Drug: APG-1387 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG-1387 and anti-PD-1 antibody
Trial: 38790900
Drug: Second-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation drug-eluting stents (rDESs)
Trial: 38793748
Drug: MVA-BN-Filo (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-BN-Filo (dose 1) and Ad26.ZEBOV (dose 2), administered intramuscularly 14 days apart
Trial: 38793748
Drug: Saline/placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline/placebo (two doses administered intramuscularly 14 days apart)
Trial: 38793748
Drug: MVA-BN-Filo (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-BN-Filo (dose 1) and Ad26.ZEBOV (dose 2)
Trial: 38794715
Drug: Standard Mediterranean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Mediterranean dietary pattern with daily energy restriction (DER + MED)
Trial: 38795087
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation (OAC) at baseline
Trial: 38795108
Drug: TEER +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEER + guideline-directed medical therapy (GDMT)
Trial: 38795703
Drug: COX inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX inhibitors plus anti-PD-1 therapy
Trial: 38796326
Drug: High-dose rotavirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rotavirus inactivated vaccine
Trial: 38796326
Drug: Medium-dose rotavirus
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose rotavirus inactivated vaccine
Trial: 38796326
Drug: Low-dose rotavirus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rotavirus inactivated vaccine
Trial: 38796422
Drug: Apalutamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide plus androgen deprivation therapy (ADT) for 6 cycles
Trial: 38796500
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics and mechanical bowel preparation
Trial: 38796619
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Conbercept
Trial: 38796619
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg Aflibercept
Trial: 38796655
Drug: Clazakizumab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab (monoclonal antibody targeting IL-6 ligand)
Trial: 38797114
Drug: Nurse-led multidomain
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led multidomain intervention including risk factors assessment, education, antiemetics, dietary strategies, and relaxation therapy
Trial: 38797183
Drug: Doxycycline PEP
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline PEP (two pills of 100 mg each orally within 72 h after condomless sex, with no more than three doses of 200 mg per week)
Trial: 38797183
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine (two intramuscular injections at enrolment and at 2 months)
Trial: 38797190
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg/kg intravenously on day 2 or 3, then once every 3 weeks for 2 years) + low-dose, single-fraction radiotherapy (8 Gy/1 fx)
Trial: 38797460
Drug: Phenoxymethyl Penicillin
RxNorm normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethyl Penicillin (Pen V arm, twice daily oral penicillin)
Trial: 38797460
Drug: Benzathine Benzyl
RxNorm normalized name: Benzathine benzylpenicillin
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Benzathine Benzyl Penicillin G (BPG arm, every-28-day intramuscular penicillin)
Trial: 38797460
Drug: Benzathine Benzyl
RxNorm normalized name: Benzathine benzylpenicillin
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Benzathine Benzyl Penicillin G (BPG arm)
Trial: 38797482
Drug: Lycopene-rich vegetable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene-rich vegetable juice providing low (13.1 mg), medium (23.9 mg), and high (31.0 mg) daily total carotenoid doses for 8 weeks.
Trial: 38797635
Drug: Cardiac index-guided
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac index-guided therapy (using intravenous fluids and dobutamine)
Trial: 38797835
Drug: Low-carbohydrate and
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate and energy-restricted (LCER) diet (Pharm-TCR: <50 g carbohydrates; ~850-1100 kcal/day; n=20)
Trial: 38797835
Drug: Treatment-as-usual (TAU;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU; n=16)
Trial: 38798396
Drug: Novel non-invasive
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel non-invasive biomarkers of GERD, BE, airway hyperreactivity (AHR), treatment efficacy, and severity of symptoms.
Trial: 39422912
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg once daily for 14 days
Trial: 38798539
Drug: Daily calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily calorie restriction (CR)
Trial: 38799274
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg (up to once daily as needed for 52 weeks)
Trial: 38799276
Drug: MEMS bottles
RxNorm normalized name: danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEMS bottles containing opioid medication for a 90-day period
Trial: 38799276
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication bottles
Trial: 38799438
Drug: CHM granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHM granules (9g/sachet, two times daily) for 7 days
Trial: 38800061
Drug: internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based cognitive behavioral therapy for insomnia (iCBT-I) for 2 months
Trial: 38800061
Drug: internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-based cognitive behavioral therapy for insomnia (iCBT-I)
Trial: 38800121
Drug: Polysaccharide hemostatic
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide hemostatic (PH) topical product
Trial: 38800408
Drug: DPCP 0.04%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPCP 0.04% ointment applied twice weekly to four in-transit metastases, concurrent with pembrolizumab 300 mg every three weeks.
Trial: 38800408
Drug: DPCP 0.04%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPCP 0.04% ointment
Trial: 38800822
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg triamcinolone
Trial: 38801606
Drug: Apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 30 mg twice daily for 16 weeks plus existing topical therapy
Trial: 38801641
Drug: Standardized Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized Chinese medicine (CM) treatment ≥3 months
Trial: 38801641
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment (non-CM cohort)
Trial: 38801826
Drug: Ad26.RSV.preF-RSV preF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.RSV.preF-RSV preF protein (one intramuscular injection)
Trial: 38802273
Drug: ECG patches
RxNorm normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECG patches and wearable bracelet
Trial: 38802569
Drug: Human amniotic
RxNorm normalized name: Human Amniotic Fluid
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human amniotic epithelial stem cells (hAESCs) injected on day -1 or day 7 post-PBMC infusion
Trial: 38802634
Drug: Venglustat in
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venglustat in combination with imiglucerase
Trial: 38802866
Drug: CPM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPM therapy (n=48)
Trial: 38802866
Drug: CPM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPM therapy
Trial: 38802888
Drug: CFRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFRT with sequential boost (50 Gy in 25 fractions, sequential boost of 10 Gy in 5 fractions to the tumor bed)